Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate

被引：2

作者：

Nham, Eliel ^{[1
,2
]}

Seong, Hye ^{[1
,2
]}

Hyun, Hakjun ^{[1
,2
]}

Yoon, Jin Gu ^{[1
,2
]}

Noh, Ji Yun ^{[1
,2
]}

Cheong, Hee Jin ^{[1
,2
]}

Kim, Woo Joo ^{[1
,2
]}

Kim, Eugene ^{[3
]}

Choi, Leejung ^{[3
]}

Lee, Jung-Min ^{[4
]}

Song, Joon Young ^{[1
,2
,5
]}

机构：

[1] Korea Univ, Coll Medi, Div Infect Dis, Dept Internal Med, Seoul, South Korea

[2] KU Med VIC K, Vaccine Innovat Ctr, RWE, Seoul, South Korea

[3] Market Access Syneos Hlth Korea, Seoul, South Korea

[4] Sanofi Korea, Seoul, South Korea

[5] Korea Univ, Korea Univ Guro Hosp, Dept Internal Med, Coll Med,Div Infect Dis, Gurodongro 148, Gurogu, Seoul 08308, South Korea

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 03期

关键词：

Influenza; high dose quadrivalent influenza vaccine; cost-effectiveness; health service; older Population; AGED; 65; YEARS; ECONOMIC-EVALUATION; SEASONAL INFLUENZA; ADULTS; EFFICACY; PREVENTION; TRIVALENT;

D O I：

10.1080/21645515.2023.2266233

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The highdose quadrivalent influenza vaccine (QIVHD) has shown improved protection against influenza and its complications in older adults. We aimed to evaluate the costeffectiveness of QIVHD compared with QIVSD among Korean adults aged >= 65 years in reducing influenzarelated disease burden. We evaluated the 2016/2017 and 2017/2018 seasons and their average values using a static decision tree model. The difference in efficacy between standard-dose (SD) and high-dose (HD) was calculated based on the results of a clinical trial comparing Fluzone (R) High-Dose Vaccine and Fluzone (R) Vaccine in older adults. Incremental cost-effectiveness ratios (ICERs) were assessed from the healthcare system perspective. A discount rate of 4.5% was applied to life-year-gained (LYG) values and utilities. We performed deterministic and probabilistic sensitivity analyses to account for both epidemiological and economic sources of uncertainty. In the analysis of the 2017/2018 season, the QIV-HD strategy generated an excess of 0.00182 life-years (Lys)/person and 0.003953 quality-adjusted life-years (QALYs)/person compared with QIV-SD. The ICER was 6,467.56 United States Dollars (USD)/QALY. In the analysis from the 2016/2017 season, QIV-HD caused a surplus of 0.00117 Lys/person and 0.003272 QALYs/person compared with QIV-SD. ICER was 7,902.46 USD /QALY. From the average data of the 2016/2017 and 2017/2018 seasons, an excess of 0.00147 Lys/person and 0.003561 QALYs/person were generated using QIV-HD compared with QIV-SD, while the ICER was 7,190.44 USD /QALY. From the healthcare system perspective, QIV-HD was a more cost-effective vaccination option in reducing influenza-related disease burden and healthcare costs in Koreans aged >= 65 years compared with QIV-SD.

引用

页数：11

共 52 条

[1]

Ahn, Development of reasonable Korean evaluation criteria for osteoporosis

[2]

[Anonymous], SEASONAL INFLUENZA V

[3]

[Anonymous], OECD Health Statistics 2019

[4] High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors [J].

Becker, Debbie L. ;

Chit, Ayman ;

DiazGranados, Carlos A. ;

Maschio, Michael ;

Yau, Eddy ;

Drummond, Michael .

Human Vaccines & Immunotherapeutics, 2016, 12 (12) :3036-3042

[5] Association of Influenza Vaccination With Cardiovascular Risk A Meta-analysis [J].

Behrouzi, Bahar ;

Bhatt, Deepak L. ;

Cannon, Christopher P. ;

Vardeny, Orly ;

Lee, Douglas S. ;

Solomon, Scott D. ;

Udell, Jacob A. .

JAMA NETWORK OPEN, 2022, 5 (04) :E228873

[6] Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis [J].

Bianculli, Pablo Manuel ;

Bellier, Lucile ;

Mangado, Ignacio Olivera ;

Perez, Carlos Grau ;

Mieres, Gustavo ;

Lazarov, Luis ;

Petitjean, Audrey ;

Dibarboure, Hugo ;

Lopez, Juan Guillermo .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)

[7]

Center of Disease Control and Prevention, Flu vaccine recommendation in COVID-19 outbreak

[8]

Center of Disease Control and Prevention, Flu vaccination

[9]

Center of Disease Control and Prevention, Preference for specific flu vaccines for seniors

[10] Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial [J].

Chang, Lee-Jah ;

Meng, Ya ;

Janosczyk, Helene ;

Landolfi, Victoria ;

Talbot, H. Keipp ;

Boone, Gary ;

Briskin, Toby ;

Cannon, Kevin ;

Christensen, Shane ;

Davis, Matthew ;

Miel, Emmanuel ;

Eck, John ;

Essink, Brandon ;

Finn, Daniel ;

Fried, David ;

Gorse, Geoffrey ;

Griffin, Carl ;

Hollister, Ripley ;

Jacqmein, Jeffry ;

Johnson, Mark ;

Julien, Katie ;

Kay, Jennifer ;

Kirstein, Judith ;

Koehler, Timothy ;

Levin, Michael ;

Martin, Earl ;

Matherne, Paul ;

Peterson, James ;

Poling, Terry ;

Saleh, Jamshid ;

Segall, Nathan ;

Seiden, David ;

Strout, Cynthia ;

Turner, Mark ;

Varano, Susann ;

Wilson, Jonathan ;

Winkle, Peter ;

Wombolt, Duane ;

Abel, Keshia ;

Babyak, Jennifer ;

Bethuel, Karine ;

Boyle, Jacqueline ;

Broudic, Karine ;

De Bruijn, Iris ;

De Sousa, Jennifer ;

Drago, Erica ;

Flores, Alma ;

Francis, Deborah ;

Hicks, Bryony ;

Fontvieille, Anne-Isabelle .

VACCINE, 2019, 37 (39) :5825-5834

← 1 2 3 4 5 6 →